Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
miércoles, octubre 21
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Celldex Therapeutics Inc
CLDX
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$30.29
0.62
2.09%
Últ. Act.: Oct 20, 5:00 PM
$30.29
0.62
2.09%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Celldex Therapeutics Financials
Celldex Therapeutics (CLDX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Celldex Therapeutics Q2 EPS $(0.94) Beats $(1.07) Estimate, Sales $22.000K Miss $954.444K Estimate
Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.07) by 12.15 percent. This is a 10.59 percent decrease over losses of $(0.85) per share
Benzinga Newsdesk
PRO
Celldex Therapeutics Q1 EPS $(1.18) Beats $(1.20) Estimate, Sales $15.000K Miss $972.222K Estimate
Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(1.18) per share which beat the analyst consensus estimate of $(1.20) by 1.67 percent. This is a 45.68 percent decrease over losses of $(0.81) per share
Benzinga Newsdesk
PRO
Celldex Therapeutics Q4 EPS $(1.22) Misses $(1.00) Estimate, Sales $100.000K Miss $1.477M Estimate
Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(1.22) per share which missed the analyst consensus estimate of $(1.00) by 21.88 percent. This is a 71.83 percent decrease over losses of $(0.71) per share
Benzinga Newsdesk
PRO
Celldex Therapeutics Q3 EPS $(1.01) Misses $(0.91) Estimate
Celldex Therapeutics (NASDAQ:CLDX) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.91) by 10.87 percent. This is a 57.81 percent decrease over losses of $(0.64) per share
Benzinga Newsdesk
PRO
Celldex Therapeutics Q2 EPS $(0.85) Misses $(0.83) Estimate, Sales $730.000K Miss $1.007M Estimate
Benzinga Newsdesk
Crude Oil Rises 6%; US Consumer Sentiment Surges In June
Avi Kapoor
